Journal Article

DKFZ-2018-01907

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Mai, E. K. ; Hielscher, T.DKFZ* ; Bertsch, U. ; Schlenzka, J. ; Salwender, H. J. ; Munder, M. ; Gerecke, C. ; Dührsen, U. ; Brossart, P. ; Neben, K. ; Hillengass, J. ; Raab, M. S. ; Merz, M. ; Baertsch, M.-A. ; Jauch, A. ; Hose, D. ; Martin, H. ; Lindemann, H.-W. ; Blau, I. W. ; Scheid, C. ; Weisel, K. C. ; Goldschmidt, H. ; Group, G. M. M. (Collaboration Author)

2019
Springer Nature London

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41375-018-0195-9

---

Contributing Institute(s):

1. Biostatistik (C060)

Research Program(s):

1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2019

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 10 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---